profilepatients

170 results found.

Top Stocks matching your search for "profile patients"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 23, 2023

“Statistically significant improvements in lung fu... See more

Dec, 3, 2022

Anavex said that the candidate's safety profil... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 21, 2023

Appears to have a clean safety profile.

Dec, 3, 2022

But what made me invest and hold through the turbu... See more

Image with triangles

Divihomes is Now Live

A new search platform that matches you with the best home improvement service providers in your area.

Instant Search & Match with Top Contractors

Instant Communication with Local Contractors

Phone Image with DiviHomes website

Millions of Unbiased User Reviews

100% Free Quotes from Top-Notch Contractors

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
TGTX

TG Therapeutics Inc

-19.05%

$18.43 - $14.92

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 6, 2023

Blood thinner Eliquis captured significant market ... See more

Jan, 4, 2023

$TGTX paid troll for Goldman or BOA, superb labeli... See more

AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 23, 2023

“Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission planned for 1H 2023” Oh, 48 weeks! !

Dec, 3, 2022

Anavex said that the candidate's safety profile also appeared to be relatively good.

Nov, 30, 2022

Anavex also better in ADAS-Cog14, and far superior safety profile.

Nov, 18, 2022

>> no clinically significant treatment-related adverse events and no serious adverse events = PERFECT SAFETY PROFILE !!

Nov, 14, 2022

$AVXL safety profile = excellent !!

Oct, 30, 2022

with Blarcamesine's outstanding safety profile this will become the #1 off label prescribed drug in the world.

Oct, 4, 2022

$AVXL for Hans, yes $avxl is great and will get approved when it’s high dose arm absolutely crushes the current SOC with a flawless safety profile.

SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 21, 2023

Appears to have a clean safety profile.

Dec, 3, 2022

But what made me invest and hold through the turbulence was watching Simu's safety profile & performance trend further develop at each trial update--peerless and unassailable.

Oct, 19, 2022

These clinical data combined with a clean safety profile and easy oral administration suggest highly encouraging and durable treatment effects for people living with Alzheimer’s disease.”

Oct, 14, 2022

Simufilam boosts soluble level of Amyloid bera42 which in turn improves or maintains cognition in Alz patients This, along with its superior safety profile, will win the approval undoubtedly!

TGTX

TG Therapeutics Inc

-19.05%

$18.43 - $14.92

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 6, 2023

Blood thinner Eliquis captured significant market from Xarelto due to its safety profile.

Jan, 4, 2023

$TGTX paid troll for Goldman or BOA, superb labeling with excellent safety profile and no warning

Jan, 4, 2023

Imagine how much Ubli could be worth to BP now with Briumvi’s best in class product profile.

Dec, 30, 2022

Clear best in class profile, less of a burdensome for pts, less time at care centers and less expensive for providers.